Comparing the effect of Alpha blocker (Silodosin) and Phosphodiesterase type 5 inhibitor (Tadalafil) in benign prostate hyperplasia patients with lower urinary tract symptoms: a single centre study

Autor:	Sanket Narayan Singh, Bhavishya Chugh, Ankur Mittal, Yogesh Kalra, Manoj Biswas, Ravinder Pal, Shikhar Agrawal, Rajeev Sarpal
Rok vydání:	2018
Předmět:	medicine.medical_specialty business.industry Urology Silodosin Hyperplasia urologic and male genital diseases medicine.disease Tadalafil Single centre Lower urinary tract symptoms cGMP-specific phosphodiesterase type 5 medicine Alpha blocker business Benign prostate medicine.drug
Zdroj:	International Surgery Journal. 5:1866
ISSN:	2349-2902 2349-3305
DOI:	10.18203/2349-2902.isj20181599
Popis:	Background: Benign prostatic hyperplasia (BPH) is a histologic diagnosis that refers to the proliferation of smooth muscle and epithelial cells within the prostatic transition zone. The aim of this systematic review is to determine the comparative effectiveness and safety of phosphodiesterase 5 inhibitors (PDE5-Is) and alpha blockers used alone or in combination for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).Methods: We analyzed 54 patients of BPH with LUTS with baseline IPSS, Qmax and PVR over one-year period. They were randomized equally in three groups i.e. group receiving alpha blocker, group receiving phosphodiesterase 5 inhibitors and group receiving combination of the two drugs. These patients were followed up at the end of 1st month and 3rd month and IPSS, Qmax and PVR was compared.Results: Out of 54, 45 patients completed the study. At the end of the study all the three groups showed significant improvement in IPSS, PVR and Qmax, all p
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::80df4781814ca15cd2d2cfcf99ee0819 https://doi.org/10.18203/2349-2902.isj20181599 Zobrazit plný text záznamu